Lung cancer continues to be the leading cause of cancer-related mortality in the United States. Brain metastases are a significant problem in patients with lung cancer and have conventionally been treated with whole-brain radiation. This article reviews the data for systemic chemotherapy to treat brain metastasis from lung cancer and examines the activity of small molecule tyrosine kinase inhibitors for the targeted therapy for brain metastases from EGFR-mutant and ALK-rearranged non–small cell lung cancer. Future directions for evaluating the role of immunotherapy in treating brain metastasis are also discussed.

Original languageEnglish
Pages (from-to)157-176
Number of pages20
JournalHematology/Oncology Clinics of North America
Issue number1
StatePublished - Feb 1 2017


  • Brain metastases
  • Chemotherapy
  • Immunotherapy
  • Lung cancer
  • Targeted therapy


Dive into the research topics of 'Systemic Treatment of Brain Metastases'. Together they form a unique fingerprint.

Cite this